Risankizumab

Resumen

Alternativas con registro en Colombia

• Basiliximab · costo anual estimado $ 2.583.167.050
• Ustekinumab · costo anual estimado $ 36.735.425
• Tocilizumab · costo anual estimado $ 31.120.265
• Canakinumab · costo anual estimado $ 356.878.385
• Secukinumab · costo anual estimado $ 60.543.645
• Ixekizumab · costo anual estimado $ 67.164.015
• Guselkumab · costo anual estimado $ 36.824.485
• Espesolimab
• Mirikizumab

Estudios clínicos principales

• A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately
  Fase 2/3 · 2018 · 1.558 participantes · AbbVie · NCT03398148
• A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
  Fase 3 · 2017 · 931 participantes · AbbVie · NCT03105128
• BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
  Fase 3 · 2016 · 684 participantes · AbbVie · NCT02694523
• A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
  Fase 3 · 2017 · 618 participantes · AbbVie · NCT03104413

Enfermedades relacionadas

• Enfermedad inflamatoria intestinal (Crohn, colitis)
• Psoriasis y artritis psoriásica

Fuentes

• Etiqueta FDA (DailyMed): Skyrizi
• EMA: Skyrizi